Is Bio-Rad trying to replicate in 2005 the success it had in 1999 when it bought Sanofi Diagnostics Pasteur for $210 million?

With $200 million in credit lined up, Bio-Rad said it is very willing to spend almost half of it to acquire reagent company BioSource of Camarillo, Calif. Trouble is, BioSource is having none of it, and has rebuffed Bio-Rad at every turn.

Last week, Bio-Rad announced an $82-million proposal for BioSource, offering $8.50 a share for the publicly held reagent company.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.